Although guinea pigs (Cavia porcellus) are popular pets and research animals, relatively little is known about appropriate analgesia and anti-inflammatory treatments for this species. Robenacoxib is a relatively new non-steroidal anti-inflammatory drug, which has shown promise in rat and mice studies, but has not been investigated in guinea pigs. The goals of this study were to determine the pharmacokinetic profile and safety of robenacoxib in 10 healthy guinea pigs. Dose-finding pilot studies will be performed in a subset of guinea pigs to determine a suitable dose of SC robenacoxib needed to reach therapeutic levels in other species. For the final study, following a 7-day minimum washout period, guinea pigs will be administered the dose of robenacoxib determined in the pilot trials as a single, SC dose. Blood will be collected from the proximal jugular vein under brief periods of isoflurane anesthesia at 0, 3, 6, 12, 24, and 48 hours post-injection using a sparse-sampling population study design and samples analyzed for plasma robenacoxib levels. Following the pharmacokinetic study, a randomized, blinded, placebo-controlled, crossover safety study will be performed. Guinea pigs will be administered a single SC dose of robenacoxib at a target dose based on pharmacokinetic data results or a comparable volume of sterile saline SC. Pelleted food intake, fecal output, fecal occult blood measurement, and body weight will be measured daily for 6 days following treatment and compared to baseline values. Biochemistry profiles will be assessed prior to and 6 days following treatment.